Literature DB >> 26236137

Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis.

Tina Zerilli, Eric Ocheretyaner.   

Abstract

Apremilast (Otezla): A new oral treatment for adults with psoriasis and psoriatic arthritis.

Entities:  

Year:  2015        PMID： 26236137      PMCID： PMC4517531     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  21 in total

1.  Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

Authors:  Kim Papp; Jennifer C Cather; Les Rosoph; Howard Sofen; Richard G Langley; Robert T Matheson; ChiaChi Hu; Robert M Day
Journal:  Lancet       Date:  2012-06-29       Impact factor: 79.321

2.  Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.

Authors:  Arthur Kavanaugh; Philip J Mease; Juan J Gomez-Reino; Adewale O Adebajo; Jürgen Wollenhaupt; Dafna D Gladman; Marla Hochfeld; Lichen L Teng; Georg Schett; Eric Lespessailles; Stephen Hall
Journal:  J Rheumatol       Date:  2015-01-15       Impact factor: 4.666

3.  Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).

Authors:  Kim Papp; Kristian Reich; Craig L Leonardi; Leon Kircik; Sergio Chimenti; Richard G B Langley; ChiaChi Hu; Randall M Stevens; Robert M Day; Kenneth B Gordon; Neil J Korman; Christopher E M Griffiths
Journal:  J Am Acad Dermatol       Date:  2015-07       Impact factor: 11.527

4.  Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.

Authors:  Peter Schafer
Journal:  Biochem Pharmacol       Date:  2012-01-10       Impact factor: 5.858

5.  Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.

Authors:  K A Papp; R Kaufmann; D Thaçi; C Hu; D Sutherland; P Rohane
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-10-03       Impact factor: 6.166

6.  Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.

Authors:  Alan Menter; Neil J Korman; Craig A Elmets; Steven R Feldman; Joel M Gelfand; Kenneth B Gordon; Alice B Gottlieb; John Y M Koo; Mark Lebwohl; Henry W Lim; Abby S Van Voorhees; Karl R Beutner; Reva Bhushan
Journal:  J Am Acad Dermatol       Date:  2009-06-03       Impact factor: 11.527

Review 7.  Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.

Authors:  Philip J Mease; April W Armstrong
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

Review 8.  New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.

Authors:  Andrew C Palfreeman; Kay E McNamee; Fiona E McCann
Journal:  Drug Des Devel Ther       Date:  2013-03-27       Impact factor: 4.162

9.  Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Authors:  Arthur Kavanaugh; Philip J Mease; Juan J Gomez-Reino; Adewale O Adebajo; Jürgen Wollenhaupt; Dafna D Gladman; Eric Lespessailles; Stephen Hall; Marla Hochfeld; ChiaChi Hu; Douglas Hough; Randall M Stevens; Georg Schett
Journal:  Ann Rheum Dis       Date:  2014-03-04       Impact factor: 19.103

10.  The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.

Authors:  Yong Liu; Simon Zhou; Yuntao Wan; Anfan Wu; Maria Palmisano
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335
View more
  15 in total

Review 1.  Development of anticancer agents targeting the Hedgehog signaling.

Authors:  Xiangqian Zhang; Ye Tian; Yanling Yang; Jijun Hao
Journal:  Cell Mol Life Sci       Date:  2017-03-17       Impact factor: 9.261

2.  Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study.

Authors:  Rieke Alten; P G Conaghan; V Strand; E Sullivan; S Blackburn; H Tian; K Gandhi; S M Jugl; A Deodhar
Journal:  Clin Rheumatol       Date:  2019-02-04       Impact factor: 2.980

3.  Apremilast in Refractory Alopecia Areata.

Authors:  Andrea Estébanez; Nuria Estébanez; Jose M Martín; Encarna Montesinos
Journal:  Int J Trichology       Date:  2019 Sep-Oct

4.  Development of Apremilast Nanoemulsion-Loaded Chitosan Gels: In Vitro Evaluations and Anti-Inflammatory and Wound Healing Studies on a Rat Model.

Authors:  Mohammed Muqtader Ahmed; Md Khalid Anwer; Farhat Fatima; Amer S Alali; Mohd Abul Kalam; Ameeduzzafar Zafar; Sultan Alshehri; Mohammed M Ghoneim
Journal:  Gels       Date:  2022-04-20

5.  Structure-property relations of a unique and systematic dataset of 19 isostructural multicomponent apremilast forms.

Authors:  Jan Jirát; Martin Babor; Luděk Ridvan; Eliška Skořepová; Michal Dušek; Miroslav Šoóš
Journal:  IUCrJ       Date:  2022-06-15       Impact factor: 5.588

6.  Protective roles of apremilast via Sirtuin 1 in atherosclerosis.

Authors:  Dongkui Sui; Hua Yu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

7.  COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.

Authors:  C Mugheddu; L Pizzatti; S Sanna; L Atzori; F Rongioletti
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-04       Impact factor: 6.166

8.  Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study.

Authors:  Giovanna Malara; Cristina Politi; Caterina Trifirò; Chiara Verduci; Graziella D'Arrigo; Alessandra Testa; Giovanni Tripepi
Journal:  Acta Derm Venereol       Date:  2021-09-15       Impact factor: 3.875

Review 9.  The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases.

Authors:  Verena Katharina Raker; Christian Becker; Kerstin Steinbrink
Journal:  Front Immunol       Date:  2016-03-31       Impact factor: 7.561

10.  Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic.

Authors:  Daniele Melis; Cristina Mugheddu; Silvia Sanna; Laura Atzori; Franco Rongioletti
Journal:  Dermatol Ther       Date:  2020-06-24       Impact factor: 3.858
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.